Gao, H., Yang, Z., Yang, X. and Rao, Y. (2017) Synthesis and Evaluation of Osimertinib Derivatives as Potent EGFR Inhibitors. Bioorganic & Medicinal Chemistry, 25, 4553-4559.
https://doi.org/10.1016/j.bmc.2017.06.004

has been cited by the following article:

• TITLE: Separation, Identification, Isolation and Characterization of Degradation Product of Osimertinib Tablets by UPLC-QTOF-MS/MS and NMR: Evaluation of In-Silico Safety Assessment for Osimertinib (OSM) and Degradation Product (DP)

  AUTHORS: Arun D. Bhutnar, Seema R. Saple, Vikas V. Vaidya

  KEYWORDS: Osimertinib Mesylate (OSM), Base Degradation, Semi-Preparative Isolation and Characterizations by HPLC, UPLC-QTOF-MS/MS, NMR Techniques

  JOURNAL NAME: Advances in Biological Chemistry, Vol.11 No.1, February 2, 2021

  ABSTRACT: The present work encompasses identification and characterization of major degradation product (DP) of OSM observed in base hydrolytic stress study. The separation of DP was carried out on a non-polar stationary phase by using high-performance liquid chromatography system (HPLC). Using waters X-bridge (250 mm × 4.6 mm, 5 μm) C18 column with gradient elution program. For the characterization study, stress samples were subjected to HPLC and UPLC-QTOF-MS/MS and based on mass fragmentation pattern, plausible structure was deduced. Further, the DP was isolated using semi-prepara- tive liquid chromatography and concentrated the fractions using lyophilization. The isolated DP was subjected to extensive 1D (1H, 13C, and DEPT-135) and 2D (COSY, HSQC and HMBC) nuclear magnetic resonance (NMR) studies to authenticate the structure. The impurity was unambiguously named as N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-metho-xy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)-3-methoxypropanamide. Add- itionally, the In-Silico structure activity relation (QSAR) assessed through statistical based software’s DEREK NexusTM, and MultiCASE, Case UltraTM widely accepted and respected software’s for DP and OSM.